ArticleEye (London, England)2025
A ten-year study of Baerveldt glaucoma drainage device in an Australian paediatric population.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood glaucoma is a rare condition that presents a significant management challenge often requiring surgical intervention. This study evaluates the epidemiology, efficacy and safety profile of Baerveldt glaucoma drainage devices (GDDs) in an Australian paediatric population over ten years.
methodsA retrospective review of all patients under 18 years who underwent anterior chamber Baerveldt 101-350 implantation between January 2014 and January 2024 in an Australian tertiary referral centre was conducted. Patient characteristics, ocular examination and surgical details were collected. Survival rates were estimated using Kaplan-Meier analysis.
resultsEighty-one Baerveldt GDDs were inserted in 80 eyes of 63 children at median 4.0 years. Prior glaucoma surgery was documented in 48.1% of cases. The most common indication was refractory glaucoma following cataract surgery (38.8%). A significant reduction in intraocular pressure (IOP) and medication requirement was observed at final follow-up (p < 0.001), with 36.3% of eyes requiring no glaucoma medications. The one-, five- and ten-year survival rates were 90.1%, 71.1% and 62.9% respectively. Twenty GDDs failed, predominantly due to elevated IOP. Complications occurred in 12.3% of cases with the most common being hypotony (4.9%) followed by tube retraction (3.7%).
conclusionBaerveldt 101-350 GDDs can provide effective long-term IOP control with a favourable safety profile. We noted a higher proportion of patients with glaucoma following cataract surgery in comparison to previous studies. Outcomes of this large single surgeon series compare favourably with existing literature and support the use of Baerveldt GDDs as a reliable option in childhood glaucoma refractory to other approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.